Clinical Trials for Coronary Artery Disease

227 coronary artery disease trials indexed, 96 currently recruiting. Updated daily from ClinicalTrials.gov.

Understanding Coronary Artery Disease

Coronary artery disease (CAD) is a condition where the arteries that supply blood to the heart muscle become narrowed or blocked. This happens because of a buildup of fatty deposits called plaque inside the artery walls. Over time, this buildup reduces blood flow, which can cause chest pain or other serious heart problems. Doctors often diagnose CAD using tests like an electrocardiogram (ECG), stress tests, or imaging studies such as coronary angiography. These tests help identify areas where blood flow is limited and assess the severity of the disease.

Symptoms of CAD typically include chest discomfort, shortness of breath, and fatigue during physical activity. Some people may experience heart palpitations or dizziness. The condition most often starts to appear in middle age or later, generally affecting adults over 45 years old. Men are more likely to develop CAD earlier than women, but the risk increases for women after menopause. Common risk factors include high blood pressure, high cholesterol, smoking, diabetes, obesity, and a family history of heart disease.

Coronary artery disease is a major health concern worldwide. It is the leading cause of death in many countries, including the United States. According to the American Heart Association, about 18.2 million adults in the U.S. have CAD, which contributes to nearly 370,000 deaths each year. The economic burden is also significant, with billions spent annually on hospitalizations and treatments. This makes understanding and managing CAD important not only for individual health but also for public health systems.

The Coronary Artery Disease Treatment Landscape

Treatment for coronary artery disease usually begins with lifestyle changes and medications aimed at reducing symptoms and preventing complications. Doctors often recommend quitting smoking, eating a heart-healthy diet, and increasing physical activity. First-line medications include aspirin to reduce blood clotting and statins to lower cholesterol levels. These treatments help slow the progression of plaque buildup and reduce the risk of heart attacks. In some cases, procedures like angioplasty may be used to open narrowed arteries.

If symptoms persist or worsen, second-line treatments may be added. These include beta-blockers, which reduce the heart’s workload and lower blood pressure, and calcium channel blockers, which help relax blood vessels. Nitroglycerin is often used to relieve chest pain quickly. For patients with more severe disease, third-line options may include advanced interventions such as coronary artery bypass grafting (CABG) surgery. Medications like ACE inhibitors or angiotensin receptor blockers (ARBs) are also prescribed to improve heart function and control blood pressure.

Despite these options, some patients do not respond well to treatment or experience side effects that limit their use. For example, statins can cause muscle pain in some individuals, and beta-blockers may lead to fatigue or dizziness. There is ongoing research to find new therapies that work better for patients with resistant disease or those who cannot tolerate existing drugs. Trials also focus on improving long-term outcomes and reducing the burden of repeat hospital visits. Addressing these gaps remains a priority in coronary artery disease care.

Why Clinical Trials Matter for Coronary Artery Disease

Clinical trials offer patients the chance to access new treatments that are not yet widely available. Participating in a trial often means closer monitoring by healthcare professionals and the opportunity to contribute to medical knowledge. Currently, there are 227 coronary artery disease clinical trials indexed on ClinicalTrials.gov, with 96 actively recruiting participants. These studies explore a range of approaches, from new medications to innovative procedures, aiming to improve patient outcomes and quality of life.

Joining a clinical trial also involves some risks. New treatments may not work as expected, and some participants receive a placebo instead of the active treatment. Additional visits to clinics and tests may be required, which can be time-consuming. Side effects from experimental treatments are also possible, and not all risks are fully known at the start of the trial. It is important for patients and caregivers to discuss these factors carefully before deciding to participate.

Clinical trials for coronary artery disease are sponsored by various organizations, including academic institutions, pharmaceutical companies, and cooperative research groups. Each sponsor plays a role in advancing knowledge and developing new therapies. ClinicalTrials.gov serves as a valuable registry that provides up-to-date information on ongoing and completed trials. This transparency helps patients, doctors, and researchers find relevant studies and track progress in the fight against coronary artery disease.

What to Look for in a Coronary Artery Disease Clinical Trial

Clinical trials are divided into four main phases that test the safety and effectiveness of treatments. Phase 1 trials focus on safety and dosage, usually with a small group of healthy volunteers or patients. Phase 2 trials test the treatment on a larger group to see if it works and to further evaluate safety. Phase 3 trials involve even more participants and compare the new treatment to the current standard. Phase 4 trials happen after a treatment is approved and monitor long-term effects and effectiveness in the general population. For coronary artery disease, many trials do not specify a phase (108 trials), while Phase 4 trials are the most common among those that do (16 trials). Phase 2 and Phase 3 trials are less common, with 7 and 6 trials respectively.

When looking at inclusion criteria for coronary artery disease trials, researchers often consider factors like age, previous treatments, and disease markers. Many trials include adults in middle to older age groups, typically 40 years and older. Participants may need to have a history of heart procedures such as angioplasty or stenting. Biomarkers like cholesterol levels, blood pressure, or imaging results showing artery blockage are also common requirements. Some trials focus on specific stages of the disease or how long a person has had coronary artery disease to better understand treatment effects at different points.

Exclusion criteria help protect patient safety and ensure clear study results. People with serious other health conditions, such as severe kidney or liver disease, may be excluded because these conditions can affect how treatments work or increase risk. Some trials exclude participants taking certain medications that might interfere with the study drug. Safety limits like blood pressure or heart function levels are often set to avoid enrolling patients who might have complications. These rules help researchers focus on the treatment’s effects without extra risks or confusing factors.

From a patient’s perspective, practical details matter. Clinical trials can last from a few weeks to several years. Visit schedules may vary from weekly to monthly, and some tests require fasting or hospital stays. Travel to the study site might be needed, which could be a challenge for some people. Before joining, it is important to ask the research team: What are the potential risks and benefits? How often will I need to visit? Will I have to change my current medications? What happens if I decide to leave the trial early? These questions help patients understand what to expect and make informed decisions.

Primary Sources and Further Reading

If you want to learn more about coronary artery disease and clinical trials, it is helpful to consult trusted sources. These organizations provide detailed information on heart health, treatment options, and ongoing research. They also offer guidance on how to participate in clinical trials safely and effectively.

Latest Research and Emerging Treatments for Coronary Artery Disease (2026)

Current coronary artery disease research includes several Phase 3 trials testing new drugs and approaches to improve patient outcomes. One study is exploring the use of intravenous acetaminophen to prevent postoperative delirium in older adults after cardiac surgery (NCT04093219). Delirium is a common complication that can affect recovery and quality of life. If this treatment proves effective, it may offer a way to reduce these risks and support smoother healing after heart procedures.

Other trials focus on reducing artery plaque and inflammation, which are key factors in coronary artery disease progression. For example, inclisiran is being tested alongside statin therapy to see if it can slow plaque buildup in patients with non-obstructive coronary artery disease (NCT05360446). Inclisiran works by lowering LDL cholesterol through a mechanism that reduces the production of a protein involved in cholesterol regulation. Similarly, a combination pill of obicetrapib and ezetimibe is under study to reduce coronary plaque in patients with high-risk atherosclerotic cardiovascular disease (NCT06305559). Obicetrapib is a drug that may help raise HDL cholesterol, while ezetimibe lowers cholesterol absorption in the gut. These new drugs for coronary artery disease aim to provide additional options for patients not fully helped by current treatments.

Another promising area of research involves anti-inflammatory treatments. Ziltivekimab, an experimental drug, is being tested in patients who recently had a heart attack (NCT07276282). Early data suggests that reducing inflammation in the arteries may help decrease plaque buildup and lower the risk of future heart problems. These studies reflect ongoing efforts to develop coronary artery disease new treatment 2026 options that address different aspects of the disease. For patients, these advances could mean better control of symptoms, slower disease progression, and improved heart health over time.

Frequently asked questions about Coronary Artery Disease trials

How do I find Coronary Artery Disease clinical trials?

The authoritative source for Coronary Artery Disease clinical trials is ClinicalTrials.gov, maintained by the U.S. National Library of Medicine. 227 coronary artery disease studies are currently indexed. You can search by entering "coronary artery disease" as the condition, then filter by recruiting status, phase, and location. TrialsAlert scans ClinicalTrials.gov daily for new coronary artery disease trials and delivers a plain-language briefing every Friday explaining what changed.

What phase are most Coronary Artery Disease trials in?

Across the 227 coronary artery disease trials TrialsAlert indexes, the most common phase is Phase 4. Early-phase studies (Phase 1 and Phase 2) test safety and initial efficacy. Phase 3 trials compare a candidate treatment against the current standard of care in larger populations and generate the evidence regulators use to approve new therapies.

How many Coronary Artery Disease clinical trials are currently recruiting?

As of the latest scan, 96 coronary artery disease trials have a "Recruiting" status on ClinicalTrials.gov, out of 227 total indexed. The recruiting figure changes daily as studies open, fill enrollment, and close. TrialsAlert subscribers are notified when a new recruiting coronary artery disease trial matches their tracked condition.

Stay informed about coronary artery disease research

Get a weekly briefing with the trials that matter most.

Start monitoring coronary artery disease trials